Red Tree, RA Capital lead $108M infusion into Bicara and its bifunctional I/O drug
Bicara Therapeutics, the Biocon spinout working on a new kind of immunotherapy, has bagged $108 million to push its lead candidate deeper into the clinic.
Its top program, BCA101, hits two familiar targets in the cancer space, EGFR and TGF-β. What Bicara aims to do, though, is create a bifunctional antibody that simultaneously blocks EGFR and uses that as a homing mechanism to trap TGF-β, a cytokine that promotes cancer growth, at the tumor site.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.